Satinder Saini, MD
Internal Medicine · Crowley, LANPI 1770634461
Payments from drug & device makers
Across 352 payments — averaging $5101.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$539K
- Novartis$533K
- AstraZeneca$275K
- Vanda Pharmaceuticals Inc.$105K
- Acrotech Biopharma Inc.$56K
- Hikma Pharmaceuticals USA$53K
- plus $236K from 27 others
Across 2 payments — averaging $5108.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$10K
What the payments were for
- Food & beverage$75998%
- Education$162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $538,606 |
| Novartis | 29 | $532,585 |
| AstraZeneca | 22 | $275,005 |
| Vanda Pharmaceuticals Inc. | 26 | $104,733 |
| Acrotech Biopharma Inc. | 18 | $55,705 |
| Hikma Pharmaceuticals USA | 6 | $53,122 |
| Pfizer | 40 | $52,669 |
| Teva Pharmaceuticals USA, Inc. | 19 | $34,915 |
| Siemens Medical Solutions USA, Inc. | 3 | $32,440 |
| Chiesi USA, Inc. | 12 | $32,370 |
| Sanofi US Services Inc. | 10 | $26,312 |
| Sanofi | 6 | $24,228 |
| Genentech, Inc. | 2 | $23,650 |
| GSK | 3 | $8,978 |
| Getinge USA Sales, LLC | 2 | $75 |
| Avanir Pharmaceuticals, Inc. | 5 | $73 |
| Ironwood Pharmaceuticals, Inc | 4 | $51 |
| Novo Nordisk | 3 | $40 |
| Exact Sciences | 1 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Lilly USA, LLC | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Vertex | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,795,860 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 673 | $316,323 |
| MounjaroTirzepatide | 143 | $193,645 |
| LinzessLinaclotide | 229 | $132,315 |
| XareltoRivaroxaban | 228 | $89,308 |
| JardianceEmpagliflozin | 120 | $86,830 |
| IngrezzaValbenazine Tosylate | 18 | $73,905 |
| OzempicSemaglutide | 57 | $71,190 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $68,202 |
| JanuviaSitagliptin Phosphate | 90 | $51,428 |
| MyrbetriqMirabegron | 181 | $49,045 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $46,293 |
| EntrestoSacubitril/Valsartan | 97 | $42,124 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $33,516 |
| FarxigaDapagliflozin Propanediol | 75 | $23,840 |
| TrulicityDulaglutide | 16 | $19,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52,669 | $316,323673 claims |
| Lilly USA, LLCMounjaro, Trulicity | $27 | $213,331159 claims |
| AbbVieLinzess | $538,606 | $132,315229 claims |
| Novo NordiskOzempic, Tresiba | $40 | $81,03284 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $8,978 | $78,772105 claims |
| GileadBiktarvy | $14 | $46,29311 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $275,005 | $45,191124 claims |
| NovartisEntresto | $532,585 | $42,12497 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $73 | $19,60325 claims |
| Sanofi-aventis U.S. LLCLantus | $12 | $10,768147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Crowley
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Lydia BazzanoNew Orleans$892K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.